Friday, 25 May 2018

You are here

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Reuters:Trump assails high drug prices, avoids direct hit on industry  https://reut.rs/2IBaFiY

Bloomber: Trump's Unimpressive Plan to Lower Drug Prices  https://bloom.bg/2I8tkmO

Financial Times: Trump blames foreign countries for high drug prices  https://on.ft.com/2IdPe4c

NY Times: 6 Takeaways From Trump’s Plans to Try to Lower Drug Prices https://nyti.ms/2IEieFS

          Trump’s Plan to Lower Drug Prices Diverges From Campaign Promise  https://nyti.ms/2wyN65D

           Trump to Drop Call for Medicare to Negotiate Lower Drug Prices  https://nyti.ms/2wAmGR1

Wall St. Journal: Trump’s Plan to Cut Drug Prices Leaves Industry Relieved https://on.wsj.com/2IDeAf6

NPR:  Trump Drug Pricing 'Blueprint' Could Take Years To Build  https://n.pr/2IyMRw5

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.

60 Minutes Drills Acthar - A Financially Crippling Drug

Acthar is in the news again. Previously a New York Times article lambasted the drug as the "single most expensive drug per patient", based on it costing Medicare  $16,2371 per patient for nearly 3100 patients. Overall, costing Medicare a half-billion US dollars per year. 

Fish Oil Fails in Dry Eye Trial

Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.

FDA Advisors Weigh COX-2 Inhibitor Safety

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?

Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.